ViiV HEALTHCARE'S MEDICINES
ViiV Exchange contains the latest information on ViiV Healthcare's medicines to help Australian based healthcare professionals stay up to date on HIV care.
DOVATO (a fixed dose combination of dolutegravir and lamivudine) is indicated for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infection in adults and adolescents (from 12 years of age weighing at least 40 kg):
- in antiretroviral treatment-naïve patients with no antiretroviral treatment history who have no known or suspected resistance to either antiretroviral component;
- or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to the integrase inhibitor class or lamivudine.
(cabotegravir prolonged-release suspension for injection and rilpivirine prolonged-release suspension for injection)
CABENUVA (cabotegravir prolonged-release suspension for injection and rilpivirine prolonged-release suspension for injection) is indicated for the treatment of HIV-1 in adults who are virologically suppressed (HIV-1 RNA <50 copies per mL) and have no known or suspected resistance to either cabotegravir or rilpivirine.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
ViiV HEALTHCARE'S CLINICAL RESOURCES
VIDEOS AND RECORDINGS
Watch experts in HIV share details of clinical studies and their opinions on the latest data.
CLINICAL AND OTHER RESOURCES
Download conference symposia, webinars, bite-sized infographics and more to help inform your HIV practice.
PBS Information: These products are listed as Section 100 items. Refer to PBS Schedule for full authority information.
Please review DOVATO and CABENUVA Product Information before prescribing. Full Product Information is available at www.viivhealthcare.com/en-au/our-hiv-medicines/
PM-AU-HVX-WCNT-220002. Date of preparation: January 2023.